Avalo Therapeutics, a clinical-stage biotechnology company headquartered in Rockville, Maryland, focuses on immune dysregulation therapies, with key assets including AVTX-009, quisovalimab, and AVTX-008. The company went public on November 13, 2015, and employs 19 people.
Avalo Therapeutics (AVTX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Avalo Therapeutics's actual EPS was -$7.95, missing the estimate of -$0.40 per share, resulting in a -1889.99% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
